Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab vs Conventional Therapy for Remission Induction in EGPA
NCT05030155Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2022; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT05030155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030155.